#134: Vorapaxar in TRA 2°P-TIMI 50; response time key in renal-denervation; rivaroxaban in EINSTEIN PE; levels of LDL cholesterol predate cancer cases; ASCERT CABG, PCI analysis; Canadian AF guidelines
Vorapaxar in TRA 2°P-TIMI 50; response time key in renal-denervation; rivaroxaban in EINSTEIN PE; levels of LDL cholesterol predate cancer cases; ASCERT CABG, PCI analysis; Canadian AF guidelines (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 30, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
JAMA: 2012-03-28, Vol. 307, No. 12, Editor's Audio Summary
Dr Zylke provides summary and commentary on the March 28, 2012 issue of JAMA, the Journal of the American Medical Association. Imatinib for Gastrointestinal Stromal Tumor, Cardiovascular Health Metrics and Mortality, Asthma Medication Costs and Health Care Use, Myotonic Dystrophy and Conduction System Disease, Lipids, Cardiovascular Events, and Statin Therapy, Are medical conferences useful?, Innovative health care models and financing. (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - March 27, 2012 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
#132: "Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey
"Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 16, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#130: FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated
FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 2, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#125: Cardiologists accused of defrauding Medicare; treat risk and not LDL-cholesterol targets; PLATO: PPI analysis "raises flag"; "recalled" Riata ICD leads: summit aims for guidance; statins: to prescribe or not to prescribe?
Cardiologists accused of defrauding Medicare; treat risk and not LDL-cholesterol targets; PLATO: PPI analysis "raises flag"; "recalled" Riata ICD leads: summit aims for guidance; statins: to prescribe or not to prescribe? (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - January 27, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#124: Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial
Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - January 20, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
The Lancet: November 23, 2011
Discussion of the long-term effectiveness and safety of statins in the prevention of heart disease. (Source: Listen to The Lancet)
Source: Listen to The Lancet - November 23, 2011 Category: General Medicine Authors: The Lancet Source Type: podcasts
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
Interview with Steven E. Nissen, MD, author of Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - November 15, 2011 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
JAMA: 2011-11-16, Vol. 306, No. 19, Author Interview
Interview with Steven E. Nissen, MD, author of Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - November 15, 2011 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
#42: Statins--Cardiovascular benefit vs diabetes risk with Dr Michael Cobble
Statins have become a cornerstone therapy in the prevention of cardiovascular disease by helping to modify the risk profile of millions of people. But what about a possible connection between statin use and diabetes? (Source: The Bob Harrington Show)
Source: The Bob Harrington Show - November 1, 2011 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial
Interview with David J. A. Jenkins, MD, author of Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - August 23, 2011 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
JAMA: 2011-08-24, Vol. 306, No. 8, Author Interview
Interview with David J. A. Jenkins, MD, author of Effect of a Dietary Portfolio of Cholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia: A Randomized Controlled Trial (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - August 23, 2011 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
#38: HDL cholesterol, niacin, and AIM-HIGH with Dr Jim Stein
Is the concept of raising HDL cholesterol still pertinent in an era of well-controlled LDL levels via statin therapy? To address this question, our guest Dr Jim Stein reviews what evidence exists to indicate low HDL cholesterol may predict heart disease.. (Source: The Bob Harrington Show)
Source: The Bob Harrington Show - July 6, 2011 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
